Please assess the completion status of the following clinical trial:

Trial Title: Phase II Open-Label Pilot Study of V3381 in Chronic Cough

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18-75 years of age~* Females must be of non child-bearing potential~* Chronic Cough ( \> 8 weeks)~* Normal Chest X-ray~* Normal Lung Function~* Idiopathic or treatment resistant cough-~Exclusion Criteria:~* Recent upper respiratory tract infection (\<4 weeks)~* Pregnancy/breast-feeding~* Current smokers or ex-smokers with \<6 months abstinence or cumulative history of \>10 pack years~* Current treatment with ACE inhibitors.~* Drug or alcohol abuse~* Uncontrolled hypertension (i.e., \>140/90 mmHg despite adequate medical therapy).~* Any cardiovascular condition that would be a contra-indication to the use of sympathomimetic amines (e.g. active angina).~* Any clinically significant neurological disorder~* Prior renal transplant, current renal dialysis.~* Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study.~* Increased risk of seizures.~* Any malignancy in the past 2 years (with the exception of basal cell carcinoma).~* Use of opioids, anticonvulsants, antidepressants (particularly MAO inhibitors).~* Any clinically significant abnormal laboratory test result(s).~* Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN) reference range (after adjustment for age) or estimated creatinine clearance \<60 mL/min.~* Total bilirubin greater than upper limit of normal reference range (with the exception of Gilbert's Syndrome) and/or alanine transaminase (ALT) \>1.5 times upper limit of normal reference ranges (after adjustment for age).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).